Key facts
- Notable investors include CDH Investments, Zijin Hi-Tech Venture Capital, Nanjing Innovation Capital Group, Nanjing Jiangbei New Area Science and Technology Investment Group, Renai Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Macera Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Macera Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Macera Therapeutics
Manufacturer of macrophage immunotherapy drugs designed to treat gastric cancer, liver cancer, prostate cancer, and other solid tumors and autoimmune diseases. The company's drugs have integrated and non-integrated molecular editing and manipulation systems, iPSC-derived immune cell differentiation systems, ligand-receptor and other information flow recognition and conduction technology platforms, enabling doctors to kill tumor cells and regulate autoimmune cell cloning.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Macera Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Macera Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Macera Therapeutics in its N-PORT filings yet. We sweep new filings monthly.